Physician profile
Yusuke Wakeshima
NPI 1215992474
$5,364.85
in general payments reported to CMS, 2019-2025
21 companies · $500 in 2025
The $500 reported for 2025 was more than what 79% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $984 · 2020: $117 · 2021: $52.39 · 2022: $144 · 2023: $103 · 2024: $3,465 · 2025: $500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,945 · Food and Beverage: $1,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,945.00 |
| Food and Beverage | $1,122.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $3,564.93 | 2023-2025 | Rs 4i Plus Sequential Stimulator |
| Boston Scientific Corporation | $505.21 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Scilex Pharmaceuticals INC. | $308.62 | 2019-2023 | Ztlido |
| Lilly USA, LLC | $240.57 | 2019-2020 | |
| Zyla Life Sciences, INC. | $163.12 | 2019 | |
| Abbott Laboratories | $98.39 | 2022 | |
| Biodelivery Sciences International, INC. | $86.98 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $53.68 | 2019 | |
| Daiichi Sankyo INC. | $45.42 | 2019 | |
| Promius Pharma LLC | $40.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.39 | 2019-2020 | |
| Kaleo, INC. | $32.99 | 2019 | |
| Supernus Pharmaceuticals, INC. | $31.47 | 2019 | |
| Ibsa Pharma INC. | $31.11 | 2021-2023 | Tirosint, Licart |
| Shionogi INC | $29.83 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $23.60 | 2019 | |
| Pfizer INC. | $18.60 | 2019 | |
| Collegium Pharmaceutical, INC. | $16.91 | 2023 | Belbuca |
| Assertio Therapeutics, INC. | $15.03 | 2019 | |
| Allergan, INC. | $14.45 | 2019 | |
| Electronic Waveform Lab, INC. | $7.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yusuke Wakeshima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.